Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study

BACKGROUND: Erlotinib and pemetrexed have been approved for the second-line treatment of non-small cell lung cancer (NSCLC). These two agents have different mechanisms of action. Combined treatment with erlotinib and pemetrexed could potentially augment the antitumor activity of either agent alone....

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Minami, Seigo, Kijima, Takashi, Takahashi, Ryo, Kida, Hiroshi, Nakatani, Takeshi, Hamaguchi, Masanari, Takeuchi, Yoshiko, Nagatomo, Izumi, Yamamoto, Suguru, Tachibana, Isao, Komuta, Kiyoshi, Kawase, Ichiro
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2012
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3437193/
https://ncbi.nlm.nih.gov/pubmed/22809298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-12-296
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia